General
Preferred name
NILUTAMIDE
Synonyms
1-(3'-Trifluoromethyl-4'-nitrophentyl)-4,4-dimethylimidazoline 2,5-dione ()
RU23908 ()
Nilandron ()
RU 23908 ()
Anadron ()
RU-23908 ()
Nilutamida ()
NSC-758683 ()
Nilutamide-d6 ()
P&D ID
PD001255
CAS
63612-50-0
1189477-66-4
Tags
available
drug
Approved by
FDA
First approval
1996
Drug indication
Prostate cancer
Neoplasm
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Nilutamide is a synthetic, non-steroidal, pure antiandrogen.
(GtoPdb)
DESCRIPTION
Nilutamide (Nilandron) is an orally active nonsteroidal androgen receptor antagonist with affinity for androgen receptors but not for progestogen, estrogen or glucocorticoid receptors. Nilutamide can be used to research prostate cancer. Nilutamide also has antischistosomal properties[1][4].
PRICE
29
DESCRIPTION
Antiandrogen
(LOPAC library)
DESCRIPTION
Androgen receptor antagonist. Orally active
(Tocriscreen Total)
DESCRIPTION
Nilutamide is a non-steroidal antiandrogen that is an antagonist of the androgen receptor. It is indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs.
(Enamine Bioactive Compounds)
DESCRIPTION
Nilutamide (RU23908), an antineoplastic hormonal agent, is mainly used in the treatment of prostate Y. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors, but not for estrogen, progestogen, or glucocorticoid receptors. Therefore, Nilutamide can block the action of androgens of testicular and adrenal origin that stimulate the growth of malignant and normal prostatic tissue. Prostate Y is mainly androgen-dependent and can be treat with chemical castration or surgical. So far, antiandrogen monotherapy has not consistently been certified to be equivalent to castration.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
0
Compound Sets
32
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
NURSA ligand set
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
44
Molecular Weight
317.06
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
2.45
TPSA
92.55
Fraction CSP3
0.33
Chiral centers
0.0
Largest ring
6.0
QED
0.51
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Androgen
Target
Androgen Receptor
AR
AR antagonist
Parasite
Indication
prostate cancer
MOA
Androgen Receptor antagonist
Therapeutic Class
Anticancer Agents
Pathway
Anti-infection
Vitamin D Related/Nuclear Receptor
Endocrinology/Hormones
Source data
